May 13 (Reuters) - Tvardi Therapeutics Inc TVRD.O:
TVARDI THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE
TVARDI THERAPEUTICS: CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AT CLOSING ANTICIPATED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2H 2026
TVARDI THERAPEUTICS: ON TRACK FOR MULTIPLE PHASE 2 DATA READOUTS WITH STAT3 INHIBITOR, TTI-101, WITH LEAD PROGRAM IN IPF EXPECTED IN 2H 2025
TVARDI THERAPEUTICS INC - COMPLETES MERGER WITH CARA THERAPEUTICS